BRIDGEWATER, N.J., Feb. 7 /PRNewswire/ -- New data showed that at 48 weeks, significantly more treatment-experienced adults with HIV-1 with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) had an undetectable viral load (defined as less than 50 HIV-1 RNA copies/mL) with INTELENCE (etravirine) tablets plus a background regimen (BR) compared with placebo plus a BR. These findings from two ongoing double-blind, placebo-controlled, randomized Phase 3 studies (DUET-1 and DUET-2) were presented at the 15th Conference on Retroviruses and Opportunistic Infections in Boston.
In the DUET-1 and -2 studies, 60 percent and 61 percent of patients in the INTELENCE arms had a confirmed undetectable viral load at 48 weeks compared with 39 percent and 41 percent of those in the placebo arms, respectively. In each study, this difference was significant [p<0.0001].
INTELENCE, a new NNRTI from Tibotec, received accelerated approval from the U.S. Food and Drug Administration (FDA) on January 18, 2008. It is the first NNRTI to receive approval in almost ten years. INTELENCE received approval based on the 24-week analysis of HIV viral load and CD4+ cell counts from the pooled DUET-1 and -2 studies. The 48-week results will be filed with the FDA for consideration of traditional approval of INTELENCE.
"Etravirine is an important new option for treatment-experienced patients with NNRTI resistance and these data build upon the 24-week data that had previously been available," said Richard Haubrich, M.D., Professor of Medicine, Division of Infectious Diseases, University of California, San Diego, and investigator in the INTELENCE Phase 3 DUET studies.
INTELENCE, in combination with other antiretroviral (ARV) agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other ARV agents.
This indication is based on Week 24 analyses from two randomized, double- blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.
The following points should be considered when initiating therapy with
-- Treatment history and, when available, resistance testing, should guide
the use of INTELENCE.
-- The use of other active antiretroviral agents with INTELENCE is
associated with an increased likelihood of treatment response.
-- In patients who have experienced virologic failure on an
NNRTI-containing regimen, do not use INTELENCE in combination with
-- The risks and benefits of INTELENCE have not been established in
pediatric patients or in treatment-nave adult patients.
DUET-1 and -2 Study Design
The DUET-1 and -2 studies, identical in design but conducted in different regions, assessed the 24- and 48-week efficacy and safety of INTELENCE in combination with a BR in treatment-experienced adult HIV-1 patients with documented evidence of NNRTI and PI resistance. The primary endpoint was the proportion of patients who achieved a confirmed undetectable viral load (less than 50 copies/mL)
Patients with HIV-1 who were eligible for the DUET studies had a viral load of greater than 5,000 copies/mL while on a stable antiretroviral therapy regimen for at least eight weeks and had evidence of at least one NNRTI- resistance-associated mutation, either at screening or from prior resistance tests, as well as evidence of three or more primary PI mutations (D30N, V32I, L33F, M46I/L, I47A/V, G48V, I50L/V, V82A/F/L/S/T, I84V, N88S, or L90M) at screening.
Participants in the DUET studies were randomized to receive INTELENCE
200 mg twice daily (599 patients) or placebo (604 patients), each given in
addition to a BR. For all patients, the BR included darunavir/ritonavir,
plus at least two investigator-selected antiretroviral drugs (N(t)RTIs with
or without enfuvirtide). The study remained double-blinded through
48-Week Efficacy Findings
-- In DUET-1, 60 percent of patients in the INTELENCE arm had a confirmed
undetectable viral load at 48 weeks compared with 39 percent of those
in the placebo arm [p<0.0001].
-- In DUET-2, 61 percent of patients in the INTELENCE arm had a confirmed
undetectable viral load at 48 weeks compared with 41 percent of those
in the placebo arm [p<0.0001].
-- In DUET-1, the mean increase in CD4+ cell count from baseline was
103 cells/mm3 in the INTELENCE arm compared with 74 cells/mm3 in the
placebo arm [p=0.0025].
-- In DUET-2, the mean increase in CD4+ cell count from baseline was
94 cells/mm3 in the INTELENCE arm compared with 72 cells/mm3 in the
placebo arm [p=0.0160].
48-Week Safety Findings
In DUET-1, the most commonly reported adverse events among patients in the INTELENCE arm vs. placebo arm were rash of any type (22 percent vs. 11 percent), diarrhea (14 percent vs. 24 percent), and nausea (15 percent vs. 15 percent).
In DUET-2, the most commonly reported adverse events among patients in the INTELENCE arm vs. placebo arm were diarrhea (22.0 percent vs. 22.6 percent), rash of any type (16.6 percent vs. 11.1 percent) and nausea (14.6 percent vs. 10.8 percent).
Important Safety Information
INTELENCE(TM) does not cure HIV infection or AIDS, and does not prevent
passing HIV to others.
-- Severe and potentially life-threatening skin reactions, including
Stevens-Johnson Syndrome, hypersensitivity reaction, and erythema
multiforme, have occurred (<0.1 percent) in patients taking INTELENCE.
Treatment with INTELENCE should be discontinued and appropriate therapy
initiated if severe rash develops
-- In general, in clinical trials, rash was mild to moderate, occurred
primarily in the second week of therapy, and was infrequent after
Week 4. Rash generally resolved within 1-2 weeks on continued therapy.
Discontinuation rate due to rash was 2 percent
-- Redistribution and/or accumulation of body fat have been observed in
patients receiving antiretroviral (ARV) therapy. The causal
relationship, mechanism, and long-term consequences of these events
have not been established
-- Immune reconstitution syndrome has been reported in patients treated
with ARV therapy, including INTELENCE
-- INTELENCE should be used with caution in patients with severe hepatic
impairment (Child-Pugh Class C) as pharmacokinetics of INTELENCE have
not been evaluated in these patients
-- The most common adverse events (>10 percent) of any intensity that
occurred at a higher rate than placebo at 24-weeks were rash (16.9
percent vs. 9.3 percent) and nausea (13.9 percent vs. 11.1 percent)
-- The most common treatment-emergent adverse reactions (Grade 2-4) that
occurred in patients receiving an INTELENCE-containing regimen vs.
placebo at 24-weeks were rash (9.0 percent vs. 3.1 percent), diarrhea
(5.2 percent vs. 9.6 percent), nausea (4.7 percent vs. 3.5 percent),
fatigue (3.3 percent vs. 4.0 percent), abdominal pain (3.0 percent vs.
2.5 percent), peripheral neuropathy (2.8 percent vs. 1.8 percent),
hypertension (2.8 percent vs. 2.2 percent), headache (2.7 percent vs.
4.1 percent), and vomiting (2.3 percent vs. 2.0 percent).
-- INTELENCE should not be co-administered with the following ARVs:
tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir,
full-dose ritonavir (600 mg bid), protease inhibitors administered
without ritonavir, and other NNRTIs
-- INTELENCE should not be co-administered with carbamazepine,
phenobarbital, phenytoin, rifampin, rifapentine, rifabutin (when part
of a regimen containing protease inhibitor/ritonavir) or products
containing St. John's wort (Hypericum perforatum)
-- INTELENCE and lopinavir/ritonavir should be co-administered with
-- Co-administration of INTELENCE with other agents such as substrates,
inhibitors, or inducers of CYP3A4, CYP2C9, and/or CYP2C19 may alter
the therapeutic effect or adverse events profile of INTELENCE or the
co-administered drug(s). This is not a complete list of potential drug
Please see full Prescribing Information for more details at INTELENCE-info.com.
INTELENCE was developed by Tibotec Pharmaceuticals Ltd. and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P. Applications for approval of INTELENCE have been submitted to the European Agency for the Evaluation of Medicinal Products (EMEA) and to regulatory authorities in other countries, including Canada, Switzerland, Russia, Australia, and South Korea.
Tibotec Therapeutics, a division of Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson, headquartered in Bridgewater, N.J., is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.
Tibotec Pharmaceuticals Ltd.
Tibotec Pharmaceuticals Ltd., a subsidiary of Johnson & Johnson, based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Yardley, PA. Tibotec is dedicated to the discovery and development of innovative HIV/AIDS drugs and anti-infectives for diseases of high unmet medical need.
Forward Looking Statement
This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual
results could vary materially from Tibotec Pharmaceuticals Ltd.'s
expectations and projections. Risks and uncertainties include general
industry conditions and competition; economic conditions, such as interest
rate and currency exchange rate fluctuations; technological advances and
patents attained by competitors; challenges inherent in new product
development, including obtaining regulatory approvals; domestic and foreign
health care reforms and governmental laws and regulations; and trends
toward health care cost containment. A further list and description of
these risks, uncertainties and other factors can be found in Exhibit 99 of
Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended
December 31, 2006. Copies of this Form 10-K, as well as subsequent filings,
are available online at http://www.sec.gov, http://www.jnj.com or on request from Tibotec
Pharmaceuticals Ltd. or Johnson & Johnson. Tibotec Pharmaceuticals Ltd.
does not undertake to update any forward-looking statements as a result of
new information or future events or developments.
Media Contact: Pamela Van Houten
Investor Relations: Lesley Fishman
|SOURCE Tibotec Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved